Responder analyses from a Phase 2b trial confirmed that bremelanotide 1.75 mg achieved statistically significant improvement across all 7 sexual function endpoints in premenopausal women with hypoactive sexual desire disorder.
7 of 7 endpoints significant at 1.75 mgBremelanotide 1.75 mg achieved statistical significance (p≤0.03) versus placebo across all seven sexual function endpoints, with MCIDs confirmed by four independent analytical methods.
What the researchers found
For the bremelanotide 1.75 mg dose in the overall modified intention-to-treat population:
- All 7 endpoints achieved statistical significance vs. placebo (p ≤ 0.03)
- Endpoints included: FSFI-desire domain, FSDS-DAO total score, FSDS-DAO items 13 and 14, and number of satisfying sexual events
- Minimal clinically important differences (MCIDs) determined by ROC curves matched expert clinical estimates
- The drug was safe and well tolerated
- These responder definitions were used in the subsequent Phase 3 RECONNECT registration trials
Multiple responder analysis methods (historical anchors, self-reported global benefit, ROC curves, cumulative distribution) converged on the same conclusions, strengthening confidence in the clinical meaningfulness of the improvements.
Why it matters
Hypoactive sexual desire disorder affects an estimated 10% of premenopausal women and had very limited treatment options before bremelanotide. This study is important not just for its clinical findings but for its methodological contribution — establishing how to measure clinically meaningful change in sexual function, a subjective and complex outcome. The 1.75 mg dose identified here became the approved dose for Vyleesi (bremelanotide), the first FDA-approved on-demand treatment for low sexual desire in women.
How the study worked
Responder analyses were performed on data from a large, controlled, Phase 2b dose-finding study of bremelanotide in premenopausal women with HSDD and mixed HSDD/FSAD. Seven patient-reported outcome endpoints were assessed using four types of responder analyses: planned analyses anchored to expert-estimated MCIDs, post hoc analyses based on self-reported global benefit, ROC curve analyses, and cumulative distribution functions. Analyses were performed for all FSD diagnoses combined, HSDD alone, and FSAD/mixed groups.
What this study cannot tell us
The MCIDs were derived from the same clinical trial data, ideally they should be validated in independent populations. The study enrolled only premenopausal women, so results may not apply to postmenopausal women. Sexual function endpoints are subjective and influenced by relationship factors, mood, and expectations — all difficult to control in clinical trials. The placebo response in sexual dysfunction trials is typically substantial, which was accounted for by the single-blind phase but may still affect interpretation. Specific response rates and effect sizes for each endpoint are not detailed in the abstract.
How to read the evidence
This is a responder analysis from a controlled Phase 2b dose-ranging clinical trial with rigorous statistical methodology using multiple validation approaches. While it does not report raw efficacy data, the convergent analyses provide strong evidence for clinically meaningful benefit at the 1.75 mg dose that was subsequently confirmed in Phase 3 trials.
When this study was published
Published in 2019, this study preceded bremelanotide's FDA approval as Vyleesi later that year. The Phase 3 RECONNECT data subsequently confirmed these Phase 2b findings.
The bigger picture
Bremelanotide is a cyclic melanocortin peptide that works through a completely different mechanism than other sexual dysfunction treatments — it activates MC4 receptors in the brain's hypothalamus, modulating neural pathways that control desire rather than blood flow (like PDE5 inhibitors for erectile dysfunction). This study helped establish the clinical trial methodology for female sexual dysfunction, a historically under-researched area. The successful translation from Phase 2b through Phase 3 to FDA approval represents one of the few peptide drug success stories in the central nervous system space.
Questions still open
- How does bremelanotide's effect size compare to flibanserin (the only other approved drug for HSDD) on these same endpoints?
- Would bremelanotide be effective in postmenopausal women with HSDD, or is the mechanism age-dependent?
- Could melanocortin peptide agonists be developed as oral formulations to replace subcutaneous injection?
Common questions
What is bremelanotide and how does it work for low sexual desire?
Did the improvements actually matter to patients, or were they just statistically significant?
Read the original research
Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide.
The journal of sexual medicine, 16(8), 1226-1235
Citation
Althof, Stanley; Derogatis, Leonard R; Greenberg, Sally; Clayton, Anita H; Jordan, Robert; Lucas, Johna; Spana, Carl. (2019). Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide.. The journal of sexual medicine, 16(8), 1226-1235. https://doi.org/10.1016/j.jsxm.2019.05.012